- Global Pharma News & Resources

Global Breast Cancer Diagnostic Market is expected to grow at a CAGR of 7.7% during the forecast period 2020-2027

A new research report published by Fior Markets with the title Breast Cancer Diagnostic Market by Type (Biopsy, Blood Tests, Imaging, Genomic Tests, Others), End-Users (Diagnostic Clinical Laboratories, Hospitals Associated Laboratories, Ambulatory Surgical centres, Cancer Research Centres), Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2020 to 2027.

The global breast cancer diagnostic market is expected to grow from USD 4.99 billion in 2019 to USD 9.04 billion by 2027, at a CAGR of 7.7% during the forecast period 2020-2027. North America holds the largest market share and is anticipated to grow further, owing to rapid technological advancement, growing patient awareness, and well-established diagnostics infrastructure. In the region, Sweden and Japan have the highest survival rate. Europe holds the second-largest share in the market, owing to increasing awareness among people regarding regular check-up for early detection of breast cancer, and funding provided by the government in R&D of breast cancer diagnosis techniques. The Asia-Pacific region is expected to witness significant growth, owing to the increasing number of patients, government investments in healthcare expenditure, and rising awareness among people regarding the benefits of early detection of breast cancer.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.


Some of the notable players in the market are Becton, NanoString Technologies, Inc., Myriad Genetics Inc., Devicor Medical Products Inc., C.R. Bard, Inc., Paragon Biosciences, Genomic Health, Dickinson and Company, Koninklijke Philips N.V., Hologic Inc., and Danaher. In July 2019, Exact Sciences Corp. entered into an agreement with Genomic Health Inc. in which they will create a leading global cancer diagnostics company.

The type segment includes biopsy, blood tests, imaging, genomic tests, and others. Imaging holds the largest market share, owing to the rising preference of screening mammography, ultrasonography, diagnostics mammography, and breast MRI. Blood test segment is anticipated to witness significant growth, due to the large number of research studies conducted by research institutes. Blood test is useful for the detection of metastatic and recurring cancers at an early stage. Based on end-user, the market is segmented into diagnostic clinical laboratories, hospitals associated laboratories, ambulatory surgical centres, and cancer research centres. Hospital Associated Laboratories holds the largest share in the market, followed by diagnostics clinical laboratories.

The factors driving the market are the rising number of breast cancer cases, increasing the need for initial and efficient detection, technological advancement, and growing insurance coverage and reimbursement for breast cancer diagnostics. Factors restraining the market growth are high cost of breast cancer diagnostics, untoward side effects of the imaging, and risks like excessive administration of barium and fluorescent contrast agents.


About the report:
The global breast cancer diagnostic market is analyzed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact Us
Mark Stone
Phone: +1-201-465-4211

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 27-Jul-2020